{"gene":"RUNX2","run_date":"2026-06-10T07:46:28","timeline":{"discoveries":[{"year":1997,"finding":"Osf2/Cbfa1 (RUNX2) was identified as the transcription factor that binds the osteoblast-specific cis-acting element OSE2 in the Osteocalcin promoter, and forced expression of Osf2/Cbfa1 in nonosteoblastic cells induces expression of the principal osteoblast-specific genes, establishing it as an osteoblast-specific transcriptional activator of osteoblast differentiation.","method":"cDNA cloning, DNA binding assays, forced expression in nonosteoblastic cells, gene expression analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct DNA binding demonstrated, functional gain-of-function in heterologous cells, foundational paper replicated extensively","pmids":["9182762"],"is_preprint":false},{"year":1997,"finding":"AML3/CBFA1 (RUNX2) is the specific AML family member present in the osteoblast-specific promoter binding complex; antibody supershift assays confirmed AML-3 is the component of this complex in primary rat osteoblasts, and antisense knockdown of runt homology domain proteins reduced alkaline phosphatase-positive cells, osteocalcin production, and mineralized nodule formation.","method":"Electrophoretic mobility shift assay (EMSA) with antibody supershift, antisense oligonucleotide knockdown, differentiation assays","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — antibody supershift directly identifies RUNX2 in the complex, loss-of-function with defined osteoblast phenotypic readout","pmids":["9215522"],"is_preprint":false},{"year":2001,"finding":"TGF-β inhibits osteoblast differentiation via Smad3, which physically interacts with CBFA1/RUNX2 and represses its transcriptional activity at the CBFA1-binding OSE2 promoter sequence in mesenchymal but not epithelial cells; Smad3 also inhibits cbfa1 gene transcription, providing a dual repression mechanism.","method":"Co-immunoprecipitation, reporter gene assays, cell-type-specific transfection, gain/loss-of-function studies","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — physical interaction confirmed by Co-IP, functional consequences demonstrated with multiple orthogonal methods, independently replicated","pmids":["11331591"],"is_preprint":false},{"year":2000,"finding":"CBFA1/RUNX2 autoregulates its own promoter through negative feedback: CBFA1 binds at least three recognition motifs in the rat CBFA1 P1 promoter and within the 5' UTR, and forced CBFA1 expression downregulates CBFA1 promoter activity; a single CBFA1 site is sufficient for transcriptional autosuppression.","method":"Deletion analysis, EMSA, promoter-reporter assays, forced expression","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct DNA binding demonstrated by EMSA, functional reporter assays, multiple orthogonal approaches in one study","pmids":["10911365"],"is_preprint":false},{"year":2002,"finding":"RUNX2 interacts with histone deacetylase 6 (HDAC6) via its carboxy-terminal domain (overlapping the nuclear matrix-targeting signal), recruits HDAC6 from the cytoplasm to chromatin, and represses the p21(CIP1/WAF1) promoter through this interaction in a trichostatin A-sensitive but trapoxin B-insensitive manner.","method":"Co-immunoprecipitation, co-localization by immunofluorescence, reporter gene assays, domain mapping, HDAC inhibitor treatment","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and co-localization with domain mapping, functional reporter assays, pharmacological confirmation","pmids":["12391164"],"is_preprint":false},{"year":2006,"finding":"BMP-2 signaling stimulates p300-mediated acetylation of RUNX2, which increases its transactivation activity and inhibits Smurf1-mediated ubiquitination and degradation; HDAC4 and HDAC5 deacetylate RUNX2, restoring susceptibility to Smurf-mediated degradation. HDAC inhibition potentiates BMP-2-stimulated osteoblast differentiation.","method":"In vivo acetylation assays, co-immunoprecipitation, ubiquitination assays, HDAC inhibitor treatment, osteoblast differentiation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct modification demonstrated biochemically, multiple enzymes identified with loss/gain-of-function, functional consequence established","pmids":["16613856"],"is_preprint":false},{"year":2005,"finding":"Smad6 physically interacts with RUNX2 (but not Smad7) and enhances Smurf1-induced RUNX2 degradation via the ubiquitin-proteasome pathway, acting as an adaptor for indirect Smurf1-mediated RUNX2 degradation independent of the PY motif.","method":"Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor studies, domain-deletion mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct protein interaction demonstrated by Co-IP, mechanism dissected with PY-motif deletion mutants, multiple controls","pmids":["16299379"],"is_preprint":false},{"year":2008,"finding":"CHIP/STUB1 E3 ubiquitin ligase interacts with RUNX2 in vitro and in vivo, promotes RUNX2 ubiquitination and proteasomal degradation, and negatively regulates osteoblast differentiation; CHIP depletion stabilizes RUNX2 and enhances osteoblast differentiation, while CHIP overexpression causes RUNX2 degradation and redirects progenitors toward adipogenesis.","method":"Co-immunoprecipitation, in vitro binding assay, ubiquitination assay, siRNA knockdown, overexpression in primary calvarial osteoblasts, differentiation assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — both interaction and ubiquitination demonstrated biochemically, bidirectional loss/gain-of-function with defined cellular phenotypes","pmids":["18541707"],"is_preprint":false},{"year":2005,"finding":"Proper subnuclear targeting of RUNX2 via its nuclear matrix-targeting signal (NMTS) is required for its osteolytic and invasive functions; point mutations in the NMTS that impair targeting to nuclear matrix sites block invasive and osteolytic properties of MDA-MB-231 breast cancer cells and reduce VEGF and MMP13 expression.","method":"Site-directed mutagenesis of NMTS, immunofluorescence localization, in vivo osteolysis model, invasion assays, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutagenesis directly links subnuclear localization to functional output, in vivo and in vitro concordant results","pmids":["15665096"],"is_preprint":false},{"year":2006,"finding":"RUNX2 shuttles between the nucleus and cytoplasm in a microtubule-dependent and CRM1-dependent manner; taxol-induced microtubule stabilization causes CRM1-dependent nuclear export of RUNX2, and RUNX2 associates with stabilized microtubules via its amino terminus and co-immunoprecipitates with alpha-tubulin.","method":"Immunofluorescence microscopy, leptomycin B (CRM1 inhibitor) treatment, taxol treatment, co-immunoprecipitation with tubulin, biochemical microtubule association assay","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (inhibitor pharmacology, Co-IP, biochemical assay), domain mapped to N-terminus","pmids":["16110492"],"is_preprint":false},{"year":2003,"finding":"Estrogen receptor (ER) physically interacts with RUNX2 as detected by co-immunoprecipitation; the interaction involves portions of RUNX2 outside the DNA binding domain and the DNA binding domain of ER, and estrogen enhances RUNX2 transcriptional activity in a dose- and ER-dependent manner without changing RUNX2 protein levels or DNA binding.","method":"Co-immunoprecipitation, two-hybrid gene expression analysis, domain deletion constructs, promoter-reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and two-hybrid both support interaction, functional consequence shown, but single lab study","pmids":["12951324"],"is_preprint":false},{"year":2002,"finding":"1,25-(OH)2-vitamin D3 (VD3) suppresses the RUNX2/Cbfa1 promoter through a functional VDR/RXR heterodimer binding element in the proximal promoter region (−92 to −16); mutation of this VDRE abolished VD3 responsiveness, and VD3 suppression required functional vitamin D receptor.","method":"Promoter deletion analysis, EMSA with antibody competition, site-directed mutagenesis of VDRE, reporter gene assays in VDR-positive and -negative cells","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct DNA binding of VDR/RXR demonstrated by EMSA, site-directed mutagenesis confirms functional element, multiple cell line controls","pmids":["11900492"],"is_preprint":false},{"year":2014,"finding":"The C-terminus of RUNX2 (encoded by exon 8) drives its biological activity in chondrocytes; nuclear import and DNA binding functions of RUNX2 are insufficient for chondrogenesis, and Runx2 directly regulates a set of cell cycle genes (Gpr132, Sfn, c-Myb, Cyclin A1) to control chondrocyte proliferation.","method":"Conditional gene deletion (chondrocyte-specific Runx2 exon 8 flox), ChIP assay for cell cycle gene promoters, histology, molecular analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with specific phenotypic readout, domain function dissected by exon deletion, direct target gene binding confirmed by ChIP","pmids":["24862038"],"is_preprint":false},{"year":2014,"finding":"Dlx5 and Mef2c directly bind to a 343-bp enhancer ~30 kb upstream of the RUNX2 distal promoter and are required for osteoblast-specific Runx2 expression; other factors (Tcf7, Ctnnb1, Sp7, Smad1, Sox6) associate with the enhancer through protein-protein interactions to synergistically activate it. The enhancer has characteristic active enhancer histone modifications (H3K4me1/2, H3K18ac, H3K27ac, H2A.Z).","method":"BAC-GFP reporter mice, serial deletion analysis, ChIP assay in primary osteoblasts, transcription factor binding site mutagenesis, chromatin immunoprecipitation for histone modifications","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vivo BAC reporter, ChIP, mutagenesis, and histone modification profiling in one rigorous study","pmids":["24692107"],"is_preprint":false},{"year":2003,"finding":"Runx2 forms a physical complex with Sp7/Osterix via its Runt homology domain; co-expressed Runx2 and Sp7 synergistically activate osteocalcin and FGF3 promoters (up to 22- and 130-fold respectively), far exceeding effects of either alone.","method":"Co-immunoprecipitation of endogenous proteins, domain-deletion mapping, promoter-reporter assays in epithelial and mesenchymal cells","journal":"Connective tissue research","confidence":"High","confidence_rationale":"Tier 2 / Strong — endogenous Co-IP with domain mapping plus multiple synergistic reporter assays, confirmed in two cell types","pmids":["25158187"],"is_preprint":false},{"year":2020,"finding":"Casein kinase 2 (CK2) phosphorylates RUNX2 and recruits the deubiquitinase HAUSP, which stabilizes RUNX2 by preventing ubiquitin-dependent proteasomal degradation. This CK2/HAUSP pathway is required for commitment of skeletal stem cells to osteoprogenitors, their maturation, and for heterotopic ossification in multiple models.","method":"In vitro kinase assay, co-immunoprecipitation, ubiquitination assays, genetic deletion models, pharmacological inhibition, heterotopic ossification models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay, direct Co-IP, functional validation in multiple in vivo models","pmids":["32385263"],"is_preprint":false},{"year":2014,"finding":"Akt increases the stability of RUNX2 protein by phosphorylating and promoting proteasomal degradation of Smurf2 (an E3 ubiquitin ligase for RUNX2), thereby alleviating Smurf2-mediated suppression of RUNX2 transcriptional activity; this mechanism does not involve direct modification of RUNX2 by Akt.","method":"Protein stability assays, ubiquitination assay, Smurf2 phosphorylation analysis, RUNX2 transcriptional activity reporter, co-immunoprecipitation","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays in one lab, indirect mechanism established, no direct phosphorylation of RUNX2 detected (negative confirmed)","pmids":["24961731"],"is_preprint":false},{"year":2008,"finding":"p68 RNA helicase (Ddx5) interacts with RUNX2 in nuclear punctate foci and functions as a co-activator of RUNX2 transcription independently of its helicase activity; RUNX2 suppresses p68 expression in calvarial progenitor cells, establishing reciprocal crosstalk.","method":"Affinity purification/proteomics to identify RUNX2-interacting proteins, co-localization by immunofluorescence, transcription reporter assays, siRNA knockdown","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics-identified interaction validated by co-localization and functional assay, single lab","pmids":["17960593"],"is_preprint":false},{"year":1999,"finding":"AML3/CBFalpha1 (RUNX2) physically interacts with steroid receptors (AR and GR) via GST pull-down; AML3/CBFalpha1 shows preferential interaction with AR over GR and is functionally required for androgen-specific activation of the Slp enhancer, as dominant-negative AML1-ETO abrogates AR induction and AML3 overexpression rescues this repression.","method":"GST pull-down, EMSA with antibody supershift, dominant-negative construct, overexpression rescue assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro interaction plus functional genetic rescue, single lab","pmids":["10521447"],"is_preprint":false},{"year":2003,"finding":"Runx2 directly binds to and activates the galectin-3 promoter at two sites; forced Runx2 expression is sufficient to induce galectin-3 transcription in mesenchymal precursors, and galectin-3 expression is absent in Runx2-deficient mice.","method":"EMSA demonstrating direct Runx2 binding to galectin-3 promoter, forced expression assays in C3H10T1/2 cells, Runx2 knockout mouse analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct DNA binding (EMSA), forced expression gain-of-function, and genetic knockout all concordant","pmids":["12604608"],"is_preprint":false},{"year":2004,"finding":"Cbfa1/RUNX2 binds to the proximal SOST promoter and contributes to differential SOST expression, as shown by gel shift and transient transfection analyses in two osteosarcoma cell lines.","method":"EMSA (gel shift) and transient transfection reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated by EMSA and confirmed functionally, but only in cell lines, single lab","pmids":["14739291"],"is_preprint":false},{"year":2004,"finding":"FGF2 activates RUNX2 via the MEK/ERK signaling pathway and increases RUNX2 phosphorylation approximately 2-fold in articular chondrocytes; MEK/ERK inhibitors block both FGF2-induced RUNX2 activation and MMP-13 promoter upregulation. The authors note it is unlikely that RUNX2 is a direct ERK1/2 substrate.","method":"Pharmacological inhibition of MEK/ERK, RUNX2 phosphorylation assay, MMP-13 promoter-reporter assay, RUNX2 overexpression","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement via pharmacological epistasis and phosphorylation assay, but direct substrate relationship not proven (noted negative)","pmids":["15564063"],"is_preprint":false},{"year":2003,"finding":"In human bone marrow stromal cells, RUNX2 osteoblastic differentiation activity increases through a posttranslational mechanism involving phosphorylation, without changes in mRNA or protein levels; immunoprecipitation and Western blot revealed increased RUNX2 phosphorylation during differentiation.","method":"Western blot, EMSA for DNA binding activity, immunoprecipitation/Western blot for phosphorylation, RT-PCR","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab, phosphorylation detected by IP/Western without site identification, multiple cell types tested","pmids":["12568398"],"is_preprint":false},{"year":2003,"finding":"Runx2 directly binds to the survivin promoter (regions −1953 to −1812 and −1485 to −1119 containing consensus Runx-binding sites) in prostate cancer cells as shown by chromatin immunoprecipitation; BMP7 restores Runx2 binding to region II and Runx2 is required for survivin transcription.","method":"Chromatin immunoprecipitation (ChIP), reporter gene deletion assay, siRNA knockdown of RUNX2","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP evidence for promoter binding, loss-of-function with mRNA readout, single lab","pmids":["19949374"],"is_preprint":false},{"year":2012,"finding":"XBP1S associates physically with RUNX2 and enhances RUNX2-induced chondrocyte hypertrophy; XBP1S overexpression accelerates hypertrophy as measured by increased type X collagen and RUNX2, while XBP1S knockdown abolishes hypertrophic differentiation.","method":"Co-immunoprecipitation of XBP1S and RUNX2, overexpression, siRNA knockdown, chondrocyte differentiation markers","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein-protein interaction by Co-IP, bidirectional functional studies, single lab","pmids":["22865880"],"is_preprint":false},{"year":2010,"finding":"RUNX2 functionally associates with TCF-4 (lacking beta-catenin binding domain) and is required for Wnt-dependent gene expression in osteoblasts; Wnt pathway induction enhances RUNX2 transcriptional potential in a beta-catenin-independent manner, and RUNX2 antisense depletion specifically suppresses Wnt-induced gene expression.","method":"Co-immunoprecipitation of RUNX2 with TCF-4, antisense depletion, reporter gene assays, prostaglandin E2 and Wnt pathway stimulation","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and antisense loss-of-function with reporter assays, but single lab study","pmids":["20093419"],"is_preprint":false},{"year":2020,"finding":"Runx2 is essential for the transdifferentiation of terminal hypertrophic chondrocytes into osteoblasts; conditional deletion of Runx2 in hypertrophic chondrocytes (Col10a1-Cre) increased their apoptosis and interrupted transdifferentiation, abolishing primary spongiosa and osteoblasts in the trabecular region at E16.5, but did not affect vascular invasion into cartilage.","method":"Conditional knockout (Runx2fl/fl Col10a1-Cre), lineage tracing, histology, immunohistochemistry, in situ hybridization","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic deletion with specific cell-type Cre, multiple phenotypic readouts, clearly separates transdifferentiation from vascular invasion","pmids":["33253203"],"is_preprint":false},{"year":2022,"finding":"Runx2 establishes chromatin accessibility in osteoblasts at cell-type-distinct regulatory regions; loss of Runx2 impairs chromatin opening at osteoblast-specific enhancers including an Sp7 distal enhancer that requires Runx2-dependent binding, as demonstrated by integrative ATAC-seq and ChIP-seq analysis in neonatal osteoblasts and chondrocytes.","method":"ATAC-seq, ChIP-seq, conditional Runx2 knockout, direct cellular reprogramming, functional enhancer reporter assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-wide chromatin accessibility and binding data combined with genetic deletion and functional enhancer validation","pmids":["36070691"],"is_preprint":false},{"year":2023,"finding":"Glutathione (GSH) biosynthesis protects RUNX2 from ROS-induced degradation; reducing GSH led to acute RUNX2 protein degradation and impaired osteoblast differentiation, while reducing ROS with catalase enhanced RUNX2 stability. In utero antioxidant therapy stabilized RUNX2 and improved bone development in Runx2+/- mice.","method":"GSH biosynthesis inhibition, catalase overexpression, RUNX2 protein stability assays, CRISPR, antioxidant treatment in Runx2+/- mouse model","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — multifaceted approach with pharmacological and genetic tools, in vivo rescue experiment, clear mechanistic link to RUNX2 stability","pmids":["37432749"],"is_preprint":false},{"year":2024,"finding":"4-Hydroxynonenal (4-HNE) directly carbonylates RUNX2 at lysine 176, increasing RUNX2 protein stability and promoting vascular smooth muscle cell calcification; mutation of K176 reduced carbonylation and eliminated 4-HNE-induced RUNX2 upregulation.","method":"Site-directed mutagenesis (K176 mutation), carbonylation assay, RUNX2 knockdown, ALDH2 knockout/transgenic mice, in vitro calcification model","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-specific modification demonstrated with mutagenesis validation, concordant in vitro and in vivo data","pmids":["38348663"],"is_preprint":false},{"year":2003,"finding":"RUNX2 is ectopically expressed in metastatic breast cancer cells and activates bone sialoprotein (BSP) expression through a Runx-binding element in the proximal −110 bp of the BSP promoter, establishing a mechanism for osteoblastic gene mimicry in breast cancer cells that preferentially metastasize to bone.","method":"Promoter deletion analysis, RUNX2 isoform-specific overexpression, reporter gene assays in breast cancer cell lines","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter element identified, isoform-specific activation tested, but single lab with reporter assays only","pmids":["12750290"],"is_preprint":false},{"year":2011,"finding":"TIEG1/KLF10 directly binds to and activates the Runx2 promoter (via its zinc-finger domain), physically associates with Runx2 protein (co-immunoprecipitation and co-localization), and co-activates Runx2 transcriptional activity; loss of TIEG1 in knockout mice reduces Runx2 expression and impairs osteoblast mineralization.","method":"Transient transfection, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, co-localization, TIEG1 KO mouse analysis, adenoviral RUNX2 rescue","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct binding, Co-IP confirms protein interaction, in vivo KO phenotype, but single lab","pmids":["21559363"],"is_preprint":false},{"year":2003,"finding":"Runx2 directly binds to the DICER promoter and regulates its expression; Runx2 knockout mice display weaker DICER expression; DICER in turn cleaves precursors of miR-335-5p and miR-17-92 cluster, establishing a Runx2/DICER/miRNA cascade in osteogenic differentiation.","method":"Luciferase reporter assay for DICER promoter, Runx2 KO mouse analysis, siRNA targeting DICER, miRNA profiling, in vivo bone defect model","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding shown by reporter assay, KO mouse validation, but ChIP not shown for DICER promoter, single lab","pmids":["27064596"],"is_preprint":false},{"year":2025,"finding":"RUNX2 is a key regulator of fibrotic gene expression in LEPR+ fibroblasts; conditional deletion of Runx2 using LeprcreERT2 or Scube2creERT2 reduces generation of pathological CTHRC1+POSTN+ fibroblasts, extracellular matrix deposition, and pulmonary fibrosis in mouse models, as identified by scRNA-seq and scATAC-seq analysis.","method":"Conditional knockout (LeprcreERT2, Scube2creERT2), scRNA-seq, scATAC-seq, mouse models of pulmonary fibrosis, genetic ablation of POSTN+ cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional deletion with two independent Cre lines, integrative genomics, multiple fibrosis models","pmids":["39910313"],"is_preprint":false},{"year":2016,"finding":"RUNX2 and Osterix (OSX) physically bind to a specific region close to the SOST transcription start site and co-ordinately activate SOST expression; co-transfection of OSX and RUNX2 activates the SOST promoter in vitro.","method":"Chromatin immunoprecipitation (ChIP), promoter-reporter assays, co-transfection in osteoblastic cells","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms binding, reporter assays confirm activation, correlation with human bone expression, single lab","pmids":["27154028"],"is_preprint":false},{"year":2003,"finding":"Cbfb (core binding factor beta) forms a heterodimer with RUNX2 and is required for efficient DNA binding of RUNX2; Cbfb stabilizes RUNX2 protein by inhibiting its ubiquitination-mediated degradation.","method":"Heterodimer interaction studies, DNA binding assays, ubiquitination assays, genetic models","journal":"Journal of bone and mineral metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional heterodimer demonstrated biochemically, stability mechanism established, but primarily a review citing experimental data","pmids":["12811622"],"is_preprint":false},{"year":2010,"finding":"Runx1 and Runx2 cooperatively regulate sternal morphogenesis and chondrocyte commitment through direct regulation of Sox5 and Sox6 promoter activity, leading to induction of alpha1(II) collagen expression; mesenchymal-cell-specific double knockout of Runx1/Runx2 completely abolishes sternum formation.","method":"Conditional knockout mice (Prx1-Cre double knockout), in situ hybridization, promoter activity assays, histology","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via double conditional KO, direct promoter regulation demonstrated, in situ hybridization confirms target genes","pmids":["20181744"],"is_preprint":false},{"year":2003,"finding":"RUNX2 directly binds to the RUNX2 promoter in osseous cells (confirmed by EMSA in competition assays), and there are at least three CBFA1 recognition motifs plus three tandemly repeated sites in the 5' UTR, establishing transcriptional autosuppression as a regulatory mechanism.","method":"EMSA with competition and antibody supershift, deletion analysis, forced expression reporter assays","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct DNA binding demonstrated by EMSA antibody supershift, functional autosuppression confirmed in reporter assays, consistent with earlier findings","pmids":["10911365"],"is_preprint":false}],"current_model":"RUNX2 is a master osteoblast/chondrocyte transcription factor that binds OSE2/Runx-consensus elements in bone-specific gene promoters (osteocalcin, bone sialoprotein, SOST, p21, survivin, galectin-3, DICER, and its own promoter) to activate or repress transcription; its activity and stability are tightly controlled by post-translational modifications including phosphorylation (activated by MAPK/CK2), acetylation (by p300; reversed by HDAC4/5), ubiquitination/degradation (mediated by Smurf1/2, CHIP, Smad6 adaptor), and deubiquitination (by HAUSP recruited via CK2 phosphorylation), while its nuclear localization and function depend on a C-terminal nuclear matrix-targeting signal and CRM1/microtubule-dependent shuttling, and its transcriptional output is modulated by physical interactions with co-regulators including CBFβ, Smad3, Sp7/Osterix, estrogen receptor, HDAC6, XBP1S, TCF-4, p68/Ddx5, TIEG1/KLF10, and KLF2."},"narrative":{"mechanistic_narrative":"RUNX2 is the master transcription factor governing osteoblast differentiation, chondrocyte maturation, and skeletal morphogenesis, originally identified as the factor binding the osteoblast-specific OSE2 element in the osteocalcin promoter whose forced expression in non-osteoblastic cells activates the osteoblast gene program [PMID:9182762, PMID:9215522]. As a sequence-specific activator, RUNX2 binds Runx-consensus elements to directly regulate a broad target repertoire including galectin-3 [PMID:12604608], SOST [PMID:14739291, PMID:27154028], survivin [PMID:19949374], DICER [PMID:27064596], bone sialoprotein [PMID:12750290], and cell-cycle genes controlling chondrocyte proliferation [PMID:24862038], and it autoregulates its own promoter through negative feedback [PMID:10911365]. Beyond classical promoter activation, RUNX2 acts as a pioneer-like factor that establishes chromatin accessibility at osteoblast-specific enhancers, including a Runx2-dependent Sp7 enhancer [PMID:36070691]. Its skeletal functions are essential and stage-specific: it drives transdifferentiation of hypertrophic chondrocytes into osteoblasts [PMID:33253203], cooperates with Runx1 to control sternal morphogenesis via Sox5/Sox6 [PMID:20181744], and its own osteoblast-specific expression is set by a distal enhancer bound by Dlx5 and Mef2c [PMID:24692107]. RUNX2 transcriptional output is shaped by physical partners including the heterodimerization factor CBFβ, which is required for efficient DNA binding and protein stability [PMID:12811622], Sp7/Osterix [PMID:25158187, PMID:27154028], and Smad3, which represses RUNX2 to mediate TGF-β inhibition of osteoblast differentiation [PMID:11331591]. RUNX2 stability and activity are extensively tuned by post-translational modification: p300-mediated acetylation enhances activity and blocks Smurf1-dependent degradation, while HDAC4/5 reverse this [PMID:16613856]; CK2 phosphorylation recruits the deubiquitinase HAUSP to stabilize RUNX2 and drive osteoprogenitor commitment [PMID:32385263]; and E3 ligases CHIP/STUB1 and Smurf1/2 (the latter via the Smad6 adaptor and antagonized by Akt) target RUNX2 for proteasomal degradation [PMID:18541707, PMID:16299379, PMID:24961731]. Redox state further controls RUNX2 abundance, as glutathione protects it from ROS-induced degradation [PMID:37432749] and 4-HNE carbonylation at Lys176 stabilizes it to promote vascular smooth muscle calcification [PMID:38348663]. Subnuclear targeting via the C-terminal nuclear matrix-targeting signal and CRM1/microtubule-dependent shuttling are required for its function in osteolytic, invasive, and metastatic contexts [PMID:15665096, PMID:16110492, PMID:12750290], and RUNX2 also drives pathological fibroblast programs in pulmonary fibrosis [PMID:39910313].","teleology":[{"year":1997,"claim":"Established RUNX2 as the osteoblast-specific transcription factor that binds the OSE2 element and is sufficient to switch on the osteoblast gene program, defining its identity as a master differentiation regulator.","evidence":"cDNA cloning, DNA-binding assays, and forced expression in non-osteoblastic cells; antibody supershift and antisense knockdown in primary osteoblasts","pmids":["9182762","9215522"],"confidence":"High","gaps":["Did not define upstream signals controlling RUNX2 expression","Did not resolve cofactor requirements for target selectivity"]},{"year":2000,"claim":"Showed RUNX2 binds and represses its own promoter, revealing a negative autoregulatory feedback loop that constrains its own levels.","evidence":"Deletion analysis, EMSA, and promoter-reporter assays with forced expression","pmids":["10911365"],"confidence":"High","gaps":["Functional consequence of autosuppression in vivo not established","Cofactors at the autoregulatory site not defined"]},{"year":2001,"claim":"Identified Smad3 as a direct RUNX2-interacting repressor, explaining how TGF-β signaling inhibits osteoblast differentiation through dual repression of RUNX2 activity and gene transcription.","evidence":"Co-IP, cell-type-specific reporter assays, gain/loss-of-function","pmids":["11331591"],"confidence":"High","gaps":["Interaction interface on RUNX2 not finely mapped","Mechanism of cell-type specificity (mesenchymal vs epithelial) unresolved"]},{"year":2003,"claim":"Defined RUNX2 partnership with the obligate heterodimer subunit CBFβ and the osteoblast factor Sp7/Osterix, establishing the core complexes required for efficient DNA binding, stability, and synergistic target activation.","evidence":"Heterodimer/DNA-binding and ubiquitination assays for CBFβ; endogenous Co-IP and synergistic reporter assays for Sp7","pmids":["12811622","25158187"],"confidence":"Medium","gaps":["Structural basis of Sp7-RUNX2 synergy not resolved","CBFβ stabilization mechanism described largely in review context"]},{"year":2003,"claim":"Expanded the direct target repertoire and showed RUNX2 can be ectopically activated outside bone, linking it to galectin-3, survivin, bone sialoprotein and cancer cell behavior.","evidence":"EMSA/ChIP, forced expression, knockout mice, and reporter assays in mesenchymal and cancer cell lines","pmids":["12604608","19949374","12750290"],"confidence":"Medium","gaps":["Some targets validated only by reporter assays in cell lines","Cofactor context for cancer-specific activation undefined"]},{"year":2006,"claim":"Revealed that RUNX2 activity and stability are governed by competing acetylation and deacetylation, integrating BMP-2 signaling with Smurf1-mediated degradation.","evidence":"In vivo acetylation, Co-IP, ubiquitination assays, HDAC inhibition, and differentiation assays; HDAC6 recruitment shown earlier","pmids":["16613856","12391164"],"confidence":"High","gaps":["Acetylation site stoichiometry not quantified","Interplay with phosphorylation marks not integrated"]},{"year":2008,"claim":"Identified E3 ligases (CHIP/STUB1, Smurf1 via Smad6 adaptor) controlling RUNX2 turnover and the osteoblast-versus-adipocyte fate decision.","evidence":"Co-IP, in vitro binding, ubiquitination assays, siRNA and overexpression with differentiation readouts","pmids":["18541707","16299379"],"confidence":"High","gaps":["Lysine residues ubiquitinated not mapped","Signals selecting among competing E3 ligases unclear"]},{"year":2006,"claim":"Established that RUNX2 subnuclear targeting via its NMTS and CRM1/microtubule-dependent shuttling are required for its functional output in osteolytic and metastatic settings.","evidence":"NMTS mutagenesis with in vivo osteolysis/invasion assays; CRM1 and taxol pharmacology plus tubulin Co-IP","pmids":["15665096","16110492"],"confidence":"High","gaps":["Identity of nuclear matrix docking partners unknown","Physiological trigger for cytoplasmic shuttling undefined"]},{"year":2014,"claim":"Dissected the C-terminal (exon 8) domain requirement for chondrocyte function and identified the distal enhancer plus Dlx5/Mef2c machinery setting osteoblast-specific RUNX2 expression.","evidence":"Conditional exon-8 deletion with ChIP; BAC-GFP reporter mice, ChIP, mutagenesis, and histone-modification profiling","pmids":["24862038","24692107"],"confidence":"High","gaps":["How C-terminal activity is molecularly transmitted to chromatin not resolved","Combinatorial enhancer logic across cell types incomplete"]},{"year":2020,"claim":"Defined a CK2/HAUSP phosphorylation-deubiquitination axis that stabilizes RUNX2 and is required for skeletal stem cell commitment and heterotopic ossification.","evidence":"In vitro kinase assay, Co-IP, ubiquitination assays, genetic deletion and pharmacological inhibition in ossification models","pmids":["32385263"],"confidence":"High","gaps":["CK2 phosphosites on RUNX2 not enumerated here","Crosstalk with E3-ligase pathways not integrated"]},{"year":2022,"claim":"Demonstrated RUNX2 acts as a chromatin-accessibility-establishing factor at cell-type-distinct osteoblast enhancers, including a Runx2-dependent Sp7 enhancer, elevating it from promoter activator to pioneer-like regulator.","evidence":"ATAC-seq, ChIP-seq, conditional knockout, reprogramming, and enhancer reporter assays in neonatal cells","pmids":["36070691"],"confidence":"High","gaps":["Mechanism of nucleosome engagement not defined","Chromatin remodeler partners not identified"]},{"year":2025,"claim":"Extended RUNX2 function beyond skeleton, showing it drives pathological fibroblast programs and matrix deposition in pulmonary fibrosis.","evidence":"Conditional deletion with two Cre lines, scRNA-seq, scATAC-seq across fibrosis models","pmids":["39910313"],"confidence":"High","gaps":["Direct fibrotic target genes not enumerated","Upstream activator of RUNX2 in LEPR+ fibroblasts unclear"]},{"year":null,"claim":"How the many post-translational modifications, cofactors, and chromatin-pioneering activities are integrated into a single decision logic that selects RUNX2 targets in different lineages and disease contexts remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking modification state to genome-wide target selection","Quantitative hierarchy among competing stabilizing/destabilizing pathways unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,3,12,19,23,27,30,36,37]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3,19,23,37]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,19,27,37]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,13,26,36]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[5,6,7,15,16,28,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5,21,25]}],"complexes":["RUNX2-CBFβ heterodimer"],"partners":["CBFB","SP7","SMAD3","HDAC6","SMAD6","STUB1","DDX5","XBP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13950","full_name":"Runt-related transcription factor 2","aliases":["Acute myeloid leukemia 3 protein","Core-binding factor subunit alpha-1","CBF-alpha-1","Oncogene AML-3","Osteoblast-specific transcription factor 2","OSF-2","Polyomavirus enhancer-binding protein 2 alpha A subunit","PEA2-alpha A","PEBP2-alpha A","SL3-3 enhancer factor 1 alpha A subunit","SL3/AKV core-binding factor alpha A subunit"],"length_aa":521,"mass_kda":56.6,"function":"Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28703881, PubMed:28738062). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q13950/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RUNX2","classification":"Not Classified","n_dependent_lines":82,"n_total_lines":1208,"dependency_fraction":0.06788079470198675},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RUNX2","total_profiled":1310},"omim":[{"mim_id":"621058","title":"NK1 HOMEOBOX 2; NKX1-2","url":"https://www.omim.org/entry/621058"},{"mim_id":"620210","title":"NEURODEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND ISCHIOPUBIC HYPOPLASIA; NEDFIH","url":"https://www.omim.org/entry/620210"},{"mim_id":"620099","title":"CLEIDOCRANIAL DYSPLASIA 2; CLCD2","url":"https://www.omim.org/entry/620099"},{"mim_id":"619820","title":"ATONAL bHLH TRANSCRIPTION FACTOR 8; ATOH8","url":"https://www.omim.org/entry/619820"},{"mim_id":"619744","title":"ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 17; ZCCHC17","url":"https://www.omim.org/entry/619744"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RUNX2"},"hgnc":{"alias_symbol":["AML3","PEBP2A1","PEBP2aA1"],"prev_symbol":["CCD","CBFA1","CCD1"]},"alphafold":{"accession":"Q13950","domains":[{"cath_id":"2.60.40.720","chopping":"101-219","consensus_level":"high","plddt":94.707,"start":101,"end":219}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13950","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13950-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13950-F1-predicted_aligned_error_v6.png","plddt_mean":58.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RUNX2","jax_strain_url":"https://www.jax.org/strain/search?query=RUNX2"},"sequence":{"accession":"Q13950","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13950.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13950/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13950"}},"corpus_meta":[{"pmid":"9182762","id":"PMC_9182762","title":"Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9182762","citation_count":3462,"is_preprint":false},{"pmid":"30987410","id":"PMC_30987410","title":"Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30987410","citation_count":600,"is_preprint":false},{"pmid":"10950158","id":"PMC_10950158","title":"Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1.","date":"2000","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10950158","citation_count":507,"is_preprint":false},{"pmid":"25340806","id":"PMC_25340806","title":"Role and regulation of RUNX2 in osteogenesis.","date":"2014","source":"European cells & materials","url":"https://pubmed.ncbi.nlm.nih.gov/25340806","citation_count":441,"is_preprint":false},{"pmid":"11331591","id":"PMC_11331591","title":"TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11331591","citation_count":438,"is_preprint":false},{"pmid":"10412038","id":"PMC_10412038","title":"Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.","date":"1999","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10412038","citation_count":394,"is_preprint":false},{"pmid":"11723115","id":"PMC_11723115","title":"Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11723115","citation_count":379,"is_preprint":false},{"pmid":"29356961","id":"PMC_29356961","title":"Runx2, an inducer of osteoblast and chondrocyte differentiation.","date":"2018","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29356961","citation_count":372,"is_preprint":false},{"pmid":"7835892","id":"PMC_7835892","title":"AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7835892","citation_count":366,"is_preprint":false},{"pmid":"9215522","id":"PMC_9215522","title":"Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex.","date":"1997","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9215522","citation_count":348,"is_preprint":false},{"pmid":"11084646","id":"PMC_11084646","title":"Cbfa1: a molecular switch in osteoblast biology.","date":"2000","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/11084646","citation_count":324,"is_preprint":false},{"pmid":"25881954","id":"PMC_25881954","title":"Runx2: Structure, function, and phosphorylation in osteoblast differentiation.","date":"2015","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/25881954","citation_count":296,"is_preprint":false},{"pmid":"16613856","id":"PMC_16613856","title":"Bone morphogenetic protein-2 stimulates Runx2 acetylation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16613856","citation_count":291,"is_preprint":false},{"pmid":"12391164","id":"PMC_12391164","title":"Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12391164","citation_count":275,"is_preprint":false},{"pmid":"21328448","id":"PMC_21328448","title":"Signaling networks in RUNX2-dependent bone development.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21328448","citation_count":259,"is_preprint":false},{"pmid":"16187316","id":"PMC_16187316","title":"Runx2: a master organizer of gene transcription in developing and maturing osteoblasts.","date":"2005","source":"Birth defects research. Part C, Embryo today : reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16187316","citation_count":255,"is_preprint":false},{"pmid":"12210716","id":"PMC_12210716","title":"Runx2, a multifunctional transcription factor in skeletal development.","date":"2002","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12210716","citation_count":255,"is_preprint":false},{"pmid":"15564063","id":"PMC_15564063","title":"Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage.","date":"2004","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/15564063","citation_count":244,"is_preprint":false},{"pmid":"11857736","id":"PMC_11857736","title":"Mutations in the RUNX2 gene in patients with cleidocranial dysplasia.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11857736","citation_count":227,"is_preprint":false},{"pmid":"19783797","id":"PMC_19783797","title":"Runx2, osx, and dspp in tooth development.","date":"2009","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19783797","citation_count":223,"is_preprint":false},{"pmid":"10911365","id":"PMC_10911365","title":"Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene.","date":"2000","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10911365","citation_count":217,"is_preprint":false},{"pmid":"12568398","id":"PMC_12568398","title":"Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/12568398","citation_count":192,"is_preprint":false},{"pmid":"17981598","id":"PMC_17981598","title":"Regulation of bone development and maintenance by Runx2.","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17981598","citation_count":189,"is_preprint":false},{"pmid":"10545612","id":"PMC_10545612","title":"CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10545612","citation_count":183,"is_preprint":false},{"pmid":"31896233","id":"PMC_31896233","title":"Molecular Mechanism of Runx2-Dependent Bone Development.","date":"2020","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/31896233","citation_count":181,"is_preprint":false},{"pmid":"12952183","id":"PMC_12952183","title":"Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation.","date":"2003","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/12952183","citation_count":181,"is_preprint":false},{"pmid":"35628587","id":"PMC_35628587","title":"Whole Aspect of Runx2 Functions in Skeletal Development.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628587","citation_count":174,"is_preprint":false},{"pmid":"11517182","id":"PMC_11517182","title":"Differential regulation of the two principal Runx2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11517182","citation_count":172,"is_preprint":false},{"pmid":"12811622","id":"PMC_12811622","title":"Requisite roles of Runx2 and Cbfb in skeletal development.","date":"2003","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12811622","citation_count":171,"is_preprint":false},{"pmid":"12750290","id":"PMC_12750290","title":"Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12750290","citation_count":165,"is_preprint":false},{"pmid":"28299652","id":"PMC_28299652","title":"Roles of Runx2 in Skeletal Development.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/28299652","citation_count":161,"is_preprint":false},{"pmid":"15665096","id":"PMC_15665096","title":"Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15665096","citation_count":149,"is_preprint":false},{"pmid":"11135373","id":"PMC_11135373","title":"Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts.","date":"2001","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11135373","citation_count":146,"is_preprint":false},{"pmid":"16079892","id":"PMC_16079892","title":"Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.","date":"2005","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/16079892","citation_count":137,"is_preprint":false},{"pmid":"19734454","id":"PMC_19734454","title":"Post-translational Regulation of Runx2 in Bone and Cartilage.","date":"2009","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19734454","citation_count":134,"is_preprint":false},{"pmid":"11900492","id":"PMC_11900492","title":"1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter.","date":"2002","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11900492","citation_count":132,"is_preprint":false},{"pmid":"14529540","id":"PMC_14529540","title":"Runx2/Cbfa1: a multifunctional regulator of bone formation.","date":"2003","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/14529540","citation_count":130,"is_preprint":false},{"pmid":"16299379","id":"PMC_16299379","title":"Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16299379","citation_count":128,"is_preprint":false},{"pmid":"24862038","id":"PMC_24862038","title":"Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24862038","citation_count":127,"is_preprint":false},{"pmid":"17026500","id":"PMC_17026500","title":"Runx2 and dental development.","date":"2006","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17026500","citation_count":117,"is_preprint":false},{"pmid":"17656144","id":"PMC_17656144","title":"Runx2: of bone and stretch.","date":"2007","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17656144","citation_count":107,"is_preprint":false},{"pmid":"16440320","id":"PMC_16440320","title":"Transcriptional co-repressors of Runx2.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16440320","citation_count":106,"is_preprint":false},{"pmid":"24692107","id":"PMC_24692107","title":"Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24692107","citation_count":102,"is_preprint":false},{"pmid":"33253203","id":"PMC_33253203","title":"Runx2 is essential for the transdifferentiation of chondrocytes into osteoblasts.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33253203","citation_count":100,"is_preprint":false},{"pmid":"12951324","id":"PMC_12951324","title":"Runx2 integrates estrogen activity in osteoblasts.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12951324","citation_count":94,"is_preprint":false},{"pmid":"18541707","id":"PMC_18541707","title":"CHIP promotes Runx2 degradation and negatively regulates osteoblast differentiation.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18541707","citation_count":94,"is_preprint":false},{"pmid":"15389629","id":"PMC_15389629","title":"Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15389629","citation_count":91,"is_preprint":false},{"pmid":"24961731","id":"PMC_24961731","title":"Akt enhances Runx2 protein stability by regulating Smurf2 function during osteoblast differentiation.","date":"2014","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/24961731","citation_count":90,"is_preprint":false},{"pmid":"31340165","id":"PMC_31340165","title":"Regulation of Runx2 by MicroRNAs in osteoblast differentiation.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31340165","citation_count":87,"is_preprint":false},{"pmid":"32788656","id":"PMC_32788656","title":"RUNX2-modifying enzymes: therapeutic targets for bone diseases.","date":"2020","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32788656","citation_count":82,"is_preprint":false},{"pmid":"32913706","id":"PMC_32913706","title":"Runx2 plays a central role in Osteoarthritis development.","date":"2019","source":"Journal of orthopaedic translation","url":"https://pubmed.ncbi.nlm.nih.gov/32913706","citation_count":81,"is_preprint":false},{"pmid":"12088880","id":"PMC_12088880","title":"Hypoxia decreases Runx2/Cbfa1 expression in human osteoblast-like cells.","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12088880","citation_count":80,"is_preprint":false},{"pmid":"20181744","id":"PMC_20181744","title":"Runx1 and Runx2 cooperate during sternal morphogenesis.","date":"2010","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20181744","citation_count":77,"is_preprint":false},{"pmid":"12604608","id":"PMC_12604608","title":"Expression of galectin-3 in skeletal tissues is controlled by Runx2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12604608","citation_count":75,"is_preprint":false},{"pmid":"27154028","id":"PMC_27154028","title":"Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27154028","citation_count":73,"is_preprint":false},{"pmid":"32385263","id":"PMC_32385263","title":"A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32385263","citation_count":72,"is_preprint":false},{"pmid":"30429507","id":"PMC_30429507","title":"KLF2 regulates osteoblast differentiation by targeting of Runx2.","date":"2018","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30429507","citation_count":71,"is_preprint":false},{"pmid":"14739291","id":"PMC_14739291","title":"Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST).","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14739291","citation_count":67,"is_preprint":false},{"pmid":"17960593","id":"PMC_17960593","title":"p68 (Ddx5) interacts with Runx2 and regulates osteoblast differentiation.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17960593","citation_count":66,"is_preprint":false},{"pmid":"23169547","id":"PMC_23169547","title":"RUNX2 in mammary gland development and breast cancer.","date":"2013","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23169547","citation_count":65,"is_preprint":false},{"pmid":"19949374","id":"PMC_19949374","title":"Runx2 regulates survivin expression in prostate cancer cells.","date":"2009","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19949374","citation_count":64,"is_preprint":false},{"pmid":"20589837","id":"PMC_20589837","title":"Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARγ and adiponectin.","date":"2010","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20589837","citation_count":63,"is_preprint":false},{"pmid":"12952188","id":"PMC_12952188","title":"Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions.","date":"2003","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/12952188","citation_count":59,"is_preprint":false},{"pmid":"36070691","id":"PMC_36070691","title":"Runx2 regulates chromatin accessibility to direct the osteoblast program at neonatal stages.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36070691","citation_count":59,"is_preprint":false},{"pmid":"16110492","id":"PMC_16110492","title":"Microtubule-dependent nuclear-cytoplasmic shuttling of Runx2.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16110492","citation_count":59,"is_preprint":false},{"pmid":"12086466","id":"PMC_12086466","title":"p107 and p130 Coordinately regulate proliferation, Cbfa1 expression, and hypertrophic differentiation during endochondral bone development.","date":"2002","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/12086466","citation_count":59,"is_preprint":false},{"pmid":"19075196","id":"PMC_19075196","title":"Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia.","date":"2008","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/19075196","citation_count":58,"is_preprint":false},{"pmid":"37432749","id":"PMC_37432749","title":"Glutathione limits RUNX2 oxidation and degradation to regulate bone formation.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/37432749","citation_count":53,"is_preprint":false},{"pmid":"31878768","id":"PMC_31878768","title":"Post-Translational Regulations of Transcriptional Activity of RUNX2.","date":"2020","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/31878768","citation_count":52,"is_preprint":false},{"pmid":"39910313","id":"PMC_39910313","title":"RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/39910313","citation_count":51,"is_preprint":false},{"pmid":"30324718","id":"PMC_30324718","title":"CircRUNX2 through has-miR-203 regulates RUNX2 to prevent osteoporosis.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30324718","citation_count":50,"is_preprint":false},{"pmid":"15838892","id":"PMC_15838892","title":"Control of RUNX2 isoform expression: the role of promoters and enhancers.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15838892","citation_count":49,"is_preprint":false},{"pmid":"18931939","id":"PMC_18931939","title":"Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma.","date":"2008","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18931939","citation_count":48,"is_preprint":false},{"pmid":"25862559","id":"PMC_25862559","title":"Myeloma cell-derived Runx2 promotes myeloma progression in bone.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25862559","citation_count":47,"is_preprint":false},{"pmid":"39337587","id":"PMC_39337587","title":"Regulation of Skeletal Development and Maintenance by Runx2 and Sp7.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39337587","citation_count":45,"is_preprint":false},{"pmid":"26404249","id":"PMC_26404249","title":"Role of RUNX2 in Breast Carcinogenesis.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26404249","citation_count":45,"is_preprint":false},{"pmid":"25079226","id":"PMC_25079226","title":"Loss of Runx2 in committed osteoblasts impairs postnatal skeletogenesis.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25079226","citation_count":45,"is_preprint":false},{"pmid":"35619284","id":"PMC_35619284","title":"RUNX2 Regulates Osteoblast Differentiation via the BMP4 Signaling Pathway.","date":"2022","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/35619284","citation_count":44,"is_preprint":false},{"pmid":"10521447","id":"PMC_10521447","title":"AML3/CBFalpha1 is required for androgen-specific activation of the enhancer of the mouse sex-limited protein (Slp) gene.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521447","citation_count":44,"is_preprint":false},{"pmid":"20093419","id":"PMC_20093419","title":"Novel links among Wnt and TGF-beta signaling and Runx2.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20093419","citation_count":44,"is_preprint":false},{"pmid":"30562548","id":"PMC_30562548","title":"Parathyroid hormone-stimulation of Runx2 during osteoblast differentiation via the regulation of lnc-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p.","date":"2018","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/30562548","citation_count":44,"is_preprint":false},{"pmid":"10689183","id":"PMC_10689183","title":"PEBP2alphaA/CBFA1 mutations in Japanese cleidocranial dysplasia patients.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10689183","citation_count":44,"is_preprint":false},{"pmid":"27064596","id":"PMC_27064596","title":"Runx2/DICER/miRNA Pathway in Regulating Osteogenesis.","date":"2016","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27064596","citation_count":43,"is_preprint":false},{"pmid":"12532326","id":"PMC_12532326","title":"IRES-dependent translational control of Cbfa1/Runx2 expression.","date":"2003","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12532326","citation_count":40,"is_preprint":false},{"pmid":"21559363","id":"PMC_21559363","title":"TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21559363","citation_count":37,"is_preprint":false},{"pmid":"25738872","id":"PMC_25738872","title":"RUNX2 and Osteosarcoma.","date":"2015","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25738872","citation_count":36,"is_preprint":false},{"pmid":"24657655","id":"PMC_24657655","title":"RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/24657655","citation_count":35,"is_preprint":false},{"pmid":"37108164","id":"PMC_37108164","title":"RUNX2 and Cancer.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37108164","citation_count":33,"is_preprint":false},{"pmid":"24222232","id":"PMC_24222232","title":"RUNX2 mutations in cleidocranial dysplasia.","date":"2013","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24222232","citation_count":33,"is_preprint":false},{"pmid":"26660506","id":"PMC_26660506","title":"GnRH regulates trophoblast invasion via RUNX2-mediated MMP2/9 expression.","date":"2015","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/26660506","citation_count":33,"is_preprint":false},{"pmid":"38348663","id":"PMC_38348663","title":"Carbonylation of Runx2 at K176 by 4-Hydroxynonenal Accelerates Vascular Calcification.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38348663","citation_count":31,"is_preprint":false},{"pmid":"17537128","id":"PMC_17537128","title":"Cbfa1/Runx2-deficiency delays bone wound healing and locally delivered Cbfa1/Runx2 promotes bone repair in animal models.","date":"2007","source":"Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society","url":"https://pubmed.ncbi.nlm.nih.gov/17537128","citation_count":31,"is_preprint":false},{"pmid":"11768584","id":"PMC_11768584","title":"Identification of novel CBFA1/RUNX2 mutations causing cleidocranial dysplasia.","date":"2001","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/11768584","citation_count":31,"is_preprint":false},{"pmid":"34667264","id":"PMC_34667264","title":"Smoc1 and Smoc2 regulate bone formation as downstream molecules of Runx2.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34667264","citation_count":29,"is_preprint":false},{"pmid":"30387127","id":"PMC_30387127","title":"Deletion of Runx2 in condylar chondrocytes disrupts TMJ tissue homeostasis.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30387127","citation_count":28,"is_preprint":false},{"pmid":"33896817","id":"PMC_33896817","title":"RUNX2 promotes malignant progression in gastric cancer by regulating COL1A1.","date":"2021","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/33896817","citation_count":28,"is_preprint":false},{"pmid":"25158187","id":"PMC_25158187","title":"Sp7 and Runx2 molecular complex synergistically regulate expression of target genes.","date":"2014","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/25158187","citation_count":27,"is_preprint":false},{"pmid":"12888002","id":"PMC_12888002","title":"Tooth eruption and cementum formation in the Runx2/Cbfa1 heterozygous mouse.","date":"2003","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/12888002","citation_count":27,"is_preprint":false},{"pmid":"22865880","id":"PMC_22865880","title":"XBP1S associates with RUNX2 and regulates chondrocyte hypertrophy.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22865880","citation_count":26,"is_preprint":false},{"pmid":"26489514","id":"PMC_26489514","title":"Runx2 contributes to the regenerative potential of the mammary epithelium.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26489514","citation_count":26,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49479,"output_tokens":9247,"usd":0.143571,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19327,"output_tokens":4459,"usd":0.104055,"stage2_stop_reason":"end_turn"},"total_usd":0.247626,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Osf2/Cbfa1 (RUNX2) was identified as the transcription factor that binds the osteoblast-specific cis-acting element OSE2 in the Osteocalcin promoter, and forced expression of Osf2/Cbfa1 in nonosteoblastic cells induces expression of the principal osteoblast-specific genes, establishing it as an osteoblast-specific transcriptional activator of osteoblast differentiation.\",\n      \"method\": \"cDNA cloning, DNA binding assays, forced expression in nonosteoblastic cells, gene expression analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct DNA binding demonstrated, functional gain-of-function in heterologous cells, foundational paper replicated extensively\",\n      \"pmids\": [\"9182762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"AML3/CBFA1 (RUNX2) is the specific AML family member present in the osteoblast-specific promoter binding complex; antibody supershift assays confirmed AML-3 is the component of this complex in primary rat osteoblasts, and antisense knockdown of runt homology domain proteins reduced alkaline phosphatase-positive cells, osteocalcin production, and mineralized nodule formation.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA) with antibody supershift, antisense oligonucleotide knockdown, differentiation assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — antibody supershift directly identifies RUNX2 in the complex, loss-of-function with defined osteoblast phenotypic readout\",\n      \"pmids\": [\"9215522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TGF-β inhibits osteoblast differentiation via Smad3, which physically interacts with CBFA1/RUNX2 and represses its transcriptional activity at the CBFA1-binding OSE2 promoter sequence in mesenchymal but not epithelial cells; Smad3 also inhibits cbfa1 gene transcription, providing a dual repression mechanism.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assays, cell-type-specific transfection, gain/loss-of-function studies\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — physical interaction confirmed by Co-IP, functional consequences demonstrated with multiple orthogonal methods, independently replicated\",\n      \"pmids\": [\"11331591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CBFA1/RUNX2 autoregulates its own promoter through negative feedback: CBFA1 binds at least three recognition motifs in the rat CBFA1 P1 promoter and within the 5' UTR, and forced CBFA1 expression downregulates CBFA1 promoter activity; a single CBFA1 site is sufficient for transcriptional autosuppression.\",\n      \"method\": \"Deletion analysis, EMSA, promoter-reporter assays, forced expression\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct DNA binding demonstrated by EMSA, functional reporter assays, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"10911365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RUNX2 interacts with histone deacetylase 6 (HDAC6) via its carboxy-terminal domain (overlapping the nuclear matrix-targeting signal), recruits HDAC6 from the cytoplasm to chromatin, and represses the p21(CIP1/WAF1) promoter through this interaction in a trichostatin A-sensitive but trapoxin B-insensitive manner.\",\n      \"method\": \"Co-immunoprecipitation, co-localization by immunofluorescence, reporter gene assays, domain mapping, HDAC inhibitor treatment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and co-localization with domain mapping, functional reporter assays, pharmacological confirmation\",\n      \"pmids\": [\"12391164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BMP-2 signaling stimulates p300-mediated acetylation of RUNX2, which increases its transactivation activity and inhibits Smurf1-mediated ubiquitination and degradation; HDAC4 and HDAC5 deacetylate RUNX2, restoring susceptibility to Smurf-mediated degradation. HDAC inhibition potentiates BMP-2-stimulated osteoblast differentiation.\",\n      \"method\": \"In vivo acetylation assays, co-immunoprecipitation, ubiquitination assays, HDAC inhibitor treatment, osteoblast differentiation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct modification demonstrated biochemically, multiple enzymes identified with loss/gain-of-function, functional consequence established\",\n      \"pmids\": [\"16613856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Smad6 physically interacts with RUNX2 (but not Smad7) and enhances Smurf1-induced RUNX2 degradation via the ubiquitin-proteasome pathway, acting as an adaptor for indirect Smurf1-mediated RUNX2 degradation independent of the PY motif.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, proteasome inhibitor studies, domain-deletion mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct protein interaction demonstrated by Co-IP, mechanism dissected with PY-motif deletion mutants, multiple controls\",\n      \"pmids\": [\"16299379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CHIP/STUB1 E3 ubiquitin ligase interacts with RUNX2 in vitro and in vivo, promotes RUNX2 ubiquitination and proteasomal degradation, and negatively regulates osteoblast differentiation; CHIP depletion stabilizes RUNX2 and enhances osteoblast differentiation, while CHIP overexpression causes RUNX2 degradation and redirects progenitors toward adipogenesis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, ubiquitination assay, siRNA knockdown, overexpression in primary calvarial osteoblasts, differentiation assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — both interaction and ubiquitination demonstrated biochemically, bidirectional loss/gain-of-function with defined cellular phenotypes\",\n      \"pmids\": [\"18541707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Proper subnuclear targeting of RUNX2 via its nuclear matrix-targeting signal (NMTS) is required for its osteolytic and invasive functions; point mutations in the NMTS that impair targeting to nuclear matrix sites block invasive and osteolytic properties of MDA-MB-231 breast cancer cells and reduce VEGF and MMP13 expression.\",\n      \"method\": \"Site-directed mutagenesis of NMTS, immunofluorescence localization, in vivo osteolysis model, invasion assays, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutagenesis directly links subnuclear localization to functional output, in vivo and in vitro concordant results\",\n      \"pmids\": [\"15665096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RUNX2 shuttles between the nucleus and cytoplasm in a microtubule-dependent and CRM1-dependent manner; taxol-induced microtubule stabilization causes CRM1-dependent nuclear export of RUNX2, and RUNX2 associates with stabilized microtubules via its amino terminus and co-immunoprecipitates with alpha-tubulin.\",\n      \"method\": \"Immunofluorescence microscopy, leptomycin B (CRM1 inhibitor) treatment, taxol treatment, co-immunoprecipitation with tubulin, biochemical microtubule association assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (inhibitor pharmacology, Co-IP, biochemical assay), domain mapped to N-terminus\",\n      \"pmids\": [\"16110492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Estrogen receptor (ER) physically interacts with RUNX2 as detected by co-immunoprecipitation; the interaction involves portions of RUNX2 outside the DNA binding domain and the DNA binding domain of ER, and estrogen enhances RUNX2 transcriptional activity in a dose- and ER-dependent manner without changing RUNX2 protein levels or DNA binding.\",\n      \"method\": \"Co-immunoprecipitation, two-hybrid gene expression analysis, domain deletion constructs, promoter-reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and two-hybrid both support interaction, functional consequence shown, but single lab study\",\n      \"pmids\": [\"12951324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"1,25-(OH)2-vitamin D3 (VD3) suppresses the RUNX2/Cbfa1 promoter through a functional VDR/RXR heterodimer binding element in the proximal promoter region (−92 to −16); mutation of this VDRE abolished VD3 responsiveness, and VD3 suppression required functional vitamin D receptor.\",\n      \"method\": \"Promoter deletion analysis, EMSA with antibody competition, site-directed mutagenesis of VDRE, reporter gene assays in VDR-positive and -negative cells\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct DNA binding of VDR/RXR demonstrated by EMSA, site-directed mutagenesis confirms functional element, multiple cell line controls\",\n      \"pmids\": [\"11900492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The C-terminus of RUNX2 (encoded by exon 8) drives its biological activity in chondrocytes; nuclear import and DNA binding functions of RUNX2 are insufficient for chondrogenesis, and Runx2 directly regulates a set of cell cycle genes (Gpr132, Sfn, c-Myb, Cyclin A1) to control chondrocyte proliferation.\",\n      \"method\": \"Conditional gene deletion (chondrocyte-specific Runx2 exon 8 flox), ChIP assay for cell cycle gene promoters, histology, molecular analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with specific phenotypic readout, domain function dissected by exon deletion, direct target gene binding confirmed by ChIP\",\n      \"pmids\": [\"24862038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Dlx5 and Mef2c directly bind to a 343-bp enhancer ~30 kb upstream of the RUNX2 distal promoter and are required for osteoblast-specific Runx2 expression; other factors (Tcf7, Ctnnb1, Sp7, Smad1, Sox6) associate with the enhancer through protein-protein interactions to synergistically activate it. The enhancer has characteristic active enhancer histone modifications (H3K4me1/2, H3K18ac, H3K27ac, H2A.Z).\",\n      \"method\": \"BAC-GFP reporter mice, serial deletion analysis, ChIP assay in primary osteoblasts, transcription factor binding site mutagenesis, chromatin immunoprecipitation for histone modifications\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vivo BAC reporter, ChIP, mutagenesis, and histone modification profiling in one rigorous study\",\n      \"pmids\": [\"24692107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Runx2 forms a physical complex with Sp7/Osterix via its Runt homology domain; co-expressed Runx2 and Sp7 synergistically activate osteocalcin and FGF3 promoters (up to 22- and 130-fold respectively), far exceeding effects of either alone.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, domain-deletion mapping, promoter-reporter assays in epithelial and mesenchymal cells\",\n      \"journal\": \"Connective tissue research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — endogenous Co-IP with domain mapping plus multiple synergistic reporter assays, confirmed in two cell types\",\n      \"pmids\": [\"25158187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Casein kinase 2 (CK2) phosphorylates RUNX2 and recruits the deubiquitinase HAUSP, which stabilizes RUNX2 by preventing ubiquitin-dependent proteasomal degradation. This CK2/HAUSP pathway is required for commitment of skeletal stem cells to osteoprogenitors, their maturation, and for heterotopic ossification in multiple models.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, ubiquitination assays, genetic deletion models, pharmacological inhibition, heterotopic ossification models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay, direct Co-IP, functional validation in multiple in vivo models\",\n      \"pmids\": [\"32385263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Akt increases the stability of RUNX2 protein by phosphorylating and promoting proteasomal degradation of Smurf2 (an E3 ubiquitin ligase for RUNX2), thereby alleviating Smurf2-mediated suppression of RUNX2 transcriptional activity; this mechanism does not involve direct modification of RUNX2 by Akt.\",\n      \"method\": \"Protein stability assays, ubiquitination assay, Smurf2 phosphorylation analysis, RUNX2 transcriptional activity reporter, co-immunoprecipitation\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays in one lab, indirect mechanism established, no direct phosphorylation of RUNX2 detected (negative confirmed)\",\n      \"pmids\": [\"24961731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"p68 RNA helicase (Ddx5) interacts with RUNX2 in nuclear punctate foci and functions as a co-activator of RUNX2 transcription independently of its helicase activity; RUNX2 suppresses p68 expression in calvarial progenitor cells, establishing reciprocal crosstalk.\",\n      \"method\": \"Affinity purification/proteomics to identify RUNX2-interacting proteins, co-localization by immunofluorescence, transcription reporter assays, siRNA knockdown\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics-identified interaction validated by co-localization and functional assay, single lab\",\n      \"pmids\": [\"17960593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"AML3/CBFalpha1 (RUNX2) physically interacts with steroid receptors (AR and GR) via GST pull-down; AML3/CBFalpha1 shows preferential interaction with AR over GR and is functionally required for androgen-specific activation of the Slp enhancer, as dominant-negative AML1-ETO abrogates AR induction and AML3 overexpression rescues this repression.\",\n      \"method\": \"GST pull-down, EMSA with antibody supershift, dominant-negative construct, overexpression rescue assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro interaction plus functional genetic rescue, single lab\",\n      \"pmids\": [\"10521447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Runx2 directly binds to and activates the galectin-3 promoter at two sites; forced Runx2 expression is sufficient to induce galectin-3 transcription in mesenchymal precursors, and galectin-3 expression is absent in Runx2-deficient mice.\",\n      \"method\": \"EMSA demonstrating direct Runx2 binding to galectin-3 promoter, forced expression assays in C3H10T1/2 cells, Runx2 knockout mouse analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct DNA binding (EMSA), forced expression gain-of-function, and genetic knockout all concordant\",\n      \"pmids\": [\"12604608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cbfa1/RUNX2 binds to the proximal SOST promoter and contributes to differential SOST expression, as shown by gel shift and transient transfection analyses in two osteosarcoma cell lines.\",\n      \"method\": \"EMSA (gel shift) and transient transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated by EMSA and confirmed functionally, but only in cell lines, single lab\",\n      \"pmids\": [\"14739291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FGF2 activates RUNX2 via the MEK/ERK signaling pathway and increases RUNX2 phosphorylation approximately 2-fold in articular chondrocytes; MEK/ERK inhibitors block both FGF2-induced RUNX2 activation and MMP-13 promoter upregulation. The authors note it is unlikely that RUNX2 is a direct ERK1/2 substrate.\",\n      \"method\": \"Pharmacological inhibition of MEK/ERK, RUNX2 phosphorylation assay, MMP-13 promoter-reporter assay, RUNX2 overexpression\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement via pharmacological epistasis and phosphorylation assay, but direct substrate relationship not proven (noted negative)\",\n      \"pmids\": [\"15564063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In human bone marrow stromal cells, RUNX2 osteoblastic differentiation activity increases through a posttranslational mechanism involving phosphorylation, without changes in mRNA or protein levels; immunoprecipitation and Western blot revealed increased RUNX2 phosphorylation during differentiation.\",\n      \"method\": \"Western blot, EMSA for DNA binding activity, immunoprecipitation/Western blot for phosphorylation, RT-PCR\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab, phosphorylation detected by IP/Western without site identification, multiple cell types tested\",\n      \"pmids\": [\"12568398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Runx2 directly binds to the survivin promoter (regions −1953 to −1812 and −1485 to −1119 containing consensus Runx-binding sites) in prostate cancer cells as shown by chromatin immunoprecipitation; BMP7 restores Runx2 binding to region II and Runx2 is required for survivin transcription.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), reporter gene deletion assay, siRNA knockdown of RUNX2\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP evidence for promoter binding, loss-of-function with mRNA readout, single lab\",\n      \"pmids\": [\"19949374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"XBP1S associates physically with RUNX2 and enhances RUNX2-induced chondrocyte hypertrophy; XBP1S overexpression accelerates hypertrophy as measured by increased type X collagen and RUNX2, while XBP1S knockdown abolishes hypertrophic differentiation.\",\n      \"method\": \"Co-immunoprecipitation of XBP1S and RUNX2, overexpression, siRNA knockdown, chondrocyte differentiation markers\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein-protein interaction by Co-IP, bidirectional functional studies, single lab\",\n      \"pmids\": [\"22865880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RUNX2 functionally associates with TCF-4 (lacking beta-catenin binding domain) and is required for Wnt-dependent gene expression in osteoblasts; Wnt pathway induction enhances RUNX2 transcriptional potential in a beta-catenin-independent manner, and RUNX2 antisense depletion specifically suppresses Wnt-induced gene expression.\",\n      \"method\": \"Co-immunoprecipitation of RUNX2 with TCF-4, antisense depletion, reporter gene assays, prostaglandin E2 and Wnt pathway stimulation\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and antisense loss-of-function with reporter assays, but single lab study\",\n      \"pmids\": [\"20093419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Runx2 is essential for the transdifferentiation of terminal hypertrophic chondrocytes into osteoblasts; conditional deletion of Runx2 in hypertrophic chondrocytes (Col10a1-Cre) increased their apoptosis and interrupted transdifferentiation, abolishing primary spongiosa and osteoblasts in the trabecular region at E16.5, but did not affect vascular invasion into cartilage.\",\n      \"method\": \"Conditional knockout (Runx2fl/fl Col10a1-Cre), lineage tracing, histology, immunohistochemistry, in situ hybridization\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic deletion with specific cell-type Cre, multiple phenotypic readouts, clearly separates transdifferentiation from vascular invasion\",\n      \"pmids\": [\"33253203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Runx2 establishes chromatin accessibility in osteoblasts at cell-type-distinct regulatory regions; loss of Runx2 impairs chromatin opening at osteoblast-specific enhancers including an Sp7 distal enhancer that requires Runx2-dependent binding, as demonstrated by integrative ATAC-seq and ChIP-seq analysis in neonatal osteoblasts and chondrocytes.\",\n      \"method\": \"ATAC-seq, ChIP-seq, conditional Runx2 knockout, direct cellular reprogramming, functional enhancer reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-wide chromatin accessibility and binding data combined with genetic deletion and functional enhancer validation\",\n      \"pmids\": [\"36070691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Glutathione (GSH) biosynthesis protects RUNX2 from ROS-induced degradation; reducing GSH led to acute RUNX2 protein degradation and impaired osteoblast differentiation, while reducing ROS with catalase enhanced RUNX2 stability. In utero antioxidant therapy stabilized RUNX2 and improved bone development in Runx2+/- mice.\",\n      \"method\": \"GSH biosynthesis inhibition, catalase overexpression, RUNX2 protein stability assays, CRISPR, antioxidant treatment in Runx2+/- mouse model\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multifaceted approach with pharmacological and genetic tools, in vivo rescue experiment, clear mechanistic link to RUNX2 stability\",\n      \"pmids\": [\"37432749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"4-Hydroxynonenal (4-HNE) directly carbonylates RUNX2 at lysine 176, increasing RUNX2 protein stability and promoting vascular smooth muscle cell calcification; mutation of K176 reduced carbonylation and eliminated 4-HNE-induced RUNX2 upregulation.\",\n      \"method\": \"Site-directed mutagenesis (K176 mutation), carbonylation assay, RUNX2 knockdown, ALDH2 knockout/transgenic mice, in vitro calcification model\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-specific modification demonstrated with mutagenesis validation, concordant in vitro and in vivo data\",\n      \"pmids\": [\"38348663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RUNX2 is ectopically expressed in metastatic breast cancer cells and activates bone sialoprotein (BSP) expression through a Runx-binding element in the proximal −110 bp of the BSP promoter, establishing a mechanism for osteoblastic gene mimicry in breast cancer cells that preferentially metastasize to bone.\",\n      \"method\": \"Promoter deletion analysis, RUNX2 isoform-specific overexpression, reporter gene assays in breast cancer cell lines\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter element identified, isoform-specific activation tested, but single lab with reporter assays only\",\n      \"pmids\": [\"12750290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIEG1/KLF10 directly binds to and activates the Runx2 promoter (via its zinc-finger domain), physically associates with Runx2 protein (co-immunoprecipitation and co-localization), and co-activates Runx2 transcriptional activity; loss of TIEG1 in knockout mice reduces Runx2 expression and impairs osteoblast mineralization.\",\n      \"method\": \"Transient transfection, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, co-localization, TIEG1 KO mouse analysis, adenoviral RUNX2 rescue\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct binding, Co-IP confirms protein interaction, in vivo KO phenotype, but single lab\",\n      \"pmids\": [\"21559363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Runx2 directly binds to the DICER promoter and regulates its expression; Runx2 knockout mice display weaker DICER expression; DICER in turn cleaves precursors of miR-335-5p and miR-17-92 cluster, establishing a Runx2/DICER/miRNA cascade in osteogenic differentiation.\",\n      \"method\": \"Luciferase reporter assay for DICER promoter, Runx2 KO mouse analysis, siRNA targeting DICER, miRNA profiling, in vivo bone defect model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding shown by reporter assay, KO mouse validation, but ChIP not shown for DICER promoter, single lab\",\n      \"pmids\": [\"27064596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RUNX2 is a key regulator of fibrotic gene expression in LEPR+ fibroblasts; conditional deletion of Runx2 using LeprcreERT2 or Scube2creERT2 reduces generation of pathological CTHRC1+POSTN+ fibroblasts, extracellular matrix deposition, and pulmonary fibrosis in mouse models, as identified by scRNA-seq and scATAC-seq analysis.\",\n      \"method\": \"Conditional knockout (LeprcreERT2, Scube2creERT2), scRNA-seq, scATAC-seq, mouse models of pulmonary fibrosis, genetic ablation of POSTN+ cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional deletion with two independent Cre lines, integrative genomics, multiple fibrosis models\",\n      \"pmids\": [\"39910313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RUNX2 and Osterix (OSX) physically bind to a specific region close to the SOST transcription start site and co-ordinately activate SOST expression; co-transfection of OSX and RUNX2 activates the SOST promoter in vitro.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter-reporter assays, co-transfection in osteoblastic cells\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms binding, reporter assays confirm activation, correlation with human bone expression, single lab\",\n      \"pmids\": [\"27154028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cbfb (core binding factor beta) forms a heterodimer with RUNX2 and is required for efficient DNA binding of RUNX2; Cbfb stabilizes RUNX2 protein by inhibiting its ubiquitination-mediated degradation.\",\n      \"method\": \"Heterodimer interaction studies, DNA binding assays, ubiquitination assays, genetic models\",\n      \"journal\": \"Journal of bone and mineral metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional heterodimer demonstrated biochemically, stability mechanism established, but primarily a review citing experimental data\",\n      \"pmids\": [\"12811622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Runx1 and Runx2 cooperatively regulate sternal morphogenesis and chondrocyte commitment through direct regulation of Sox5 and Sox6 promoter activity, leading to induction of alpha1(II) collagen expression; mesenchymal-cell-specific double knockout of Runx1/Runx2 completely abolishes sternum formation.\",\n      \"method\": \"Conditional knockout mice (Prx1-Cre double knockout), in situ hybridization, promoter activity assays, histology\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via double conditional KO, direct promoter regulation demonstrated, in situ hybridization confirms target genes\",\n      \"pmids\": [\"20181744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RUNX2 directly binds to the RUNX2 promoter in osseous cells (confirmed by EMSA in competition assays), and there are at least three CBFA1 recognition motifs plus three tandemly repeated sites in the 5' UTR, establishing transcriptional autosuppression as a regulatory mechanism.\",\n      \"method\": \"EMSA with competition and antibody supershift, deletion analysis, forced expression reporter assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct DNA binding demonstrated by EMSA antibody supershift, functional autosuppression confirmed in reporter assays, consistent with earlier findings\",\n      \"pmids\": [\"10911365\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RUNX2 is a master osteoblast/chondrocyte transcription factor that binds OSE2/Runx-consensus elements in bone-specific gene promoters (osteocalcin, bone sialoprotein, SOST, p21, survivin, galectin-3, DICER, and its own promoter) to activate or repress transcription; its activity and stability are tightly controlled by post-translational modifications including phosphorylation (activated by MAPK/CK2), acetylation (by p300; reversed by HDAC4/5), ubiquitination/degradation (mediated by Smurf1/2, CHIP, Smad6 adaptor), and deubiquitination (by HAUSP recruited via CK2 phosphorylation), while its nuclear localization and function depend on a C-terminal nuclear matrix-targeting signal and CRM1/microtubule-dependent shuttling, and its transcriptional output is modulated by physical interactions with co-regulators including CBFβ, Smad3, Sp7/Osterix, estrogen receptor, HDAC6, XBP1S, TCF-4, p68/Ddx5, TIEG1/KLF10, and KLF2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RUNX2 is the master transcription factor governing osteoblast differentiation, chondrocyte maturation, and skeletal morphogenesis, originally identified as the factor binding the osteoblast-specific OSE2 element in the osteocalcin promoter whose forced expression in non-osteoblastic cells activates the osteoblast gene program [#0, #1]. As a sequence-specific activator, RUNX2 binds Runx-consensus elements to directly regulate a broad target repertoire including galectin-3 [#19], SOST [#20, #34], survivin [#23], DICER [#32], bone sialoprotein [#30], and cell-cycle genes controlling chondrocyte proliferation [#12], and it autoregulates its own promoter through negative feedback [#3, #37]. Beyond classical promoter activation, RUNX2 acts as a pioneer-like factor that establishes chromatin accessibility at osteoblast-specific enhancers, including a Runx2-dependent Sp7 enhancer [#27]. Its skeletal functions are essential and stage-specific: it drives transdifferentiation of hypertrophic chondrocytes into osteoblasts [#26], cooperates with Runx1 to control sternal morphogenesis via Sox5/Sox6 [#36], and its own osteoblast-specific expression is set by a distal enhancer bound by Dlx5 and Mef2c [#13]. RUNX2 transcriptional output is shaped by physical partners including the heterodimerization factor CBF\\u03b2, which is required for efficient DNA binding and protein stability [#35], Sp7/Osterix [#14, #34], and Smad3, which represses RUNX2 to mediate TGF-\\u03b2 inhibition of osteoblast differentiation [#2]. RUNX2 stability and activity are extensively tuned by post-translational modification: p300-mediated acetylation enhances activity and blocks Smurf1-dependent degradation, while HDAC4/5 reverse this [#5]; CK2 phosphorylation recruits the deubiquitinase HAUSP to stabilize RUNX2 and drive osteoprogenitor commitment [#15]; and E3 ligases CHIP/STUB1 and Smurf1/2 (the latter via the Smad6 adaptor and antagonized by Akt) target RUNX2 for proteasomal degradation [#7, #6, #16]. Redox state further controls RUNX2 abundance, as glutathione protects it from ROS-induced degradation [#28] and 4-HNE carbonylation at Lys176 stabilizes it to promote vascular smooth muscle calcification [#29]. Subnuclear targeting via the C-terminal nuclear matrix-targeting signal and CRM1/microtubule-dependent shuttling are required for its function in osteolytic, invasive, and metastatic contexts [#8, #9, #30], and RUNX2 also drives pathological fibroblast programs in pulmonary fibrosis [#33].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established RUNX2 as the osteoblast-specific transcription factor that binds the OSE2 element and is sufficient to switch on the osteoblast gene program, defining its identity as a master differentiation regulator.\",\n      \"evidence\": \"cDNA cloning, DNA-binding assays, and forced expression in non-osteoblastic cells; antibody supershift and antisense knockdown in primary osteoblasts\",\n      \"pmids\": [\"9182762\", \"9215522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define upstream signals controlling RUNX2 expression\", \"Did not resolve cofactor requirements for target selectivity\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed RUNX2 binds and represses its own promoter, revealing a negative autoregulatory feedback loop that constrains its own levels.\",\n      \"evidence\": \"Deletion analysis, EMSA, and promoter-reporter assays with forced expression\",\n      \"pmids\": [\"10911365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of autosuppression in vivo not established\", \"Cofactors at the autoregulatory site not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified Smad3 as a direct RUNX2-interacting repressor, explaining how TGF-\\u03b2 signaling inhibits osteoblast differentiation through dual repression of RUNX2 activity and gene transcription.\",\n      \"evidence\": \"Co-IP, cell-type-specific reporter assays, gain/loss-of-function\",\n      \"pmids\": [\"11331591\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction interface on RUNX2 not finely mapped\", \"Mechanism of cell-type specificity (mesenchymal vs epithelial) unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined RUNX2 partnership with the obligate heterodimer subunit CBF\\u03b2 and the osteoblast factor Sp7/Osterix, establishing the core complexes required for efficient DNA binding, stability, and synergistic target activation.\",\n      \"evidence\": \"Heterodimer/DNA-binding and ubiquitination assays for CBF\\u03b2; endogenous Co-IP and synergistic reporter assays for Sp7\",\n      \"pmids\": [\"12811622\", \"25158187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of Sp7-RUNX2 synergy not resolved\", \"CBF\\u03b2 stabilization mechanism described largely in review context\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Expanded the direct target repertoire and showed RUNX2 can be ectopically activated outside bone, linking it to galectin-3, survivin, bone sialoprotein and cancer cell behavior.\",\n      \"evidence\": \"EMSA/ChIP, forced expression, knockout mice, and reporter assays in mesenchymal and cancer cell lines\",\n      \"pmids\": [\"12604608\", \"19949374\", \"12750290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Some targets validated only by reporter assays in cell lines\", \"Cofactor context for cancer-specific activation undefined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed that RUNX2 activity and stability are governed by competing acetylation and deacetylation, integrating BMP-2 signaling with Smurf1-mediated degradation.\",\n      \"evidence\": \"In vivo acetylation, Co-IP, ubiquitination assays, HDAC inhibition, and differentiation assays; HDAC6 recruitment shown earlier\",\n      \"pmids\": [\"16613856\", \"12391164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetylation site stoichiometry not quantified\", \"Interplay with phosphorylation marks not integrated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified E3 ligases (CHIP/STUB1, Smurf1 via Smad6 adaptor) controlling RUNX2 turnover and the osteoblast-versus-adipocyte fate decision.\",\n      \"evidence\": \"Co-IP, in vitro binding, ubiquitination assays, siRNA and overexpression with differentiation readouts\",\n      \"pmids\": [\"18541707\", \"16299379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lysine residues ubiquitinated not mapped\", \"Signals selecting among competing E3 ligases unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that RUNX2 subnuclear targeting via its NMTS and CRM1/microtubule-dependent shuttling are required for its functional output in osteolytic and metastatic settings.\",\n      \"evidence\": \"NMTS mutagenesis with in vivo osteolysis/invasion assays; CRM1 and taxol pharmacology plus tubulin Co-IP\",\n      \"pmids\": [\"15665096\", \"16110492\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of nuclear matrix docking partners unknown\", \"Physiological trigger for cytoplasmic shuttling undefined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Dissected the C-terminal (exon 8) domain requirement for chondrocyte function and identified the distal enhancer plus Dlx5/Mef2c machinery setting osteoblast-specific RUNX2 expression.\",\n      \"evidence\": \"Conditional exon-8 deletion with ChIP; BAC-GFP reporter mice, ChIP, mutagenesis, and histone-modification profiling\",\n      \"pmids\": [\"24862038\", \"24692107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How C-terminal activity is molecularly transmitted to chromatin not resolved\", \"Combinatorial enhancer logic across cell types incomplete\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a CK2/HAUSP phosphorylation-deubiquitination axis that stabilizes RUNX2 and is required for skeletal stem cell commitment and heterotopic ossification.\",\n      \"evidence\": \"In vitro kinase assay, Co-IP, ubiquitination assays, genetic deletion and pharmacological inhibition in ossification models\",\n      \"pmids\": [\"32385263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CK2 phosphosites on RUNX2 not enumerated here\", \"Crosstalk with E3-ligase pathways not integrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated RUNX2 acts as a chromatin-accessibility-establishing factor at cell-type-distinct osteoblast enhancers, including a Runx2-dependent Sp7 enhancer, elevating it from promoter activator to pioneer-like regulator.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq, conditional knockout, reprogramming, and enhancer reporter assays in neonatal cells\",\n      \"pmids\": [\"36070691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of nucleosome engagement not defined\", \"Chromatin remodeler partners not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended RUNX2 function beyond skeleton, showing it drives pathological fibroblast programs and matrix deposition in pulmonary fibrosis.\",\n      \"evidence\": \"Conditional deletion with two Cre lines, scRNA-seq, scATAC-seq across fibrosis models\",\n      \"pmids\": [\"39910313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct fibrotic target genes not enumerated\", \"Upstream activator of RUNX2 in LEPR+ fibroblasts unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many post-translational modifications, cofactors, and chromatin-pioneering activities are integrated into a single decision logic that selects RUNX2 targets in different lineages and disease contexts remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking modification state to genome-wide target selection\", \"Quantitative hierarchy among competing stabilizing/destabilizing pathways unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 3, 12, 19, 23, 27, 30, 36, 37]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3, 19, 23, 37]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 19, 27, 37]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 13, 26, 36]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [5, 6, 7, 15, 16, 28, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5, 21, 25]}\n    ],\n    \"complexes\": [\"RUNX2-CBF\\u03b2 heterodimer\"],\n    \"partners\": [\"CBFB\", \"SP7\", \"SMAD3\", \"HDAC6\", \"SMAD6\", \"STUB1\", \"DDX5\", \"XBP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}